By Iain Gilbert
Date: Thursday 04 Jan 2024
(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.
By Iain Gilbert
Date: Tuesday 02 Jan 2024
(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.
By Josh White
Date: Friday 21 Apr 2023
(Sharecast News) - Liquid biopsy specialist Angle described a "breakthrough year" in its 2022 results on Friday, with both FDA clearance and positive results from the ovarian cancer study being achieved.
Currency | UK Pounds |
Share Price | 12.00p |
Change Today | 0.25p |
% Change | 2.13 % |
52 Week High | 31.40 |
52 Week Low | 9.25 |
Volume | 1,308,627 |
Shares Issued | 260.58m |
Market Cap | £31.27m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
17:08 | 18,846 @ 12.00p |
16:24 | 12,354 @ 12.11p |
16:19 | 5,000 @ 12.11p |
16:13 | 35,000 @ 11.70p |
15:49 | 17,238 @ 11.77p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research